Andersen-Tawil syndrome screening: Difference between revisions
Line 17: | Line 17: | ||
* There is insufficient evidence to recommend routine screening for Andersen-Tawil syndrome. | * There is insufficient evidence to recommend routine screening for Andersen-Tawil syndrome. | ||
* But when a patient with positive KCNJ2 mutation and have no symtoms in Andersen-Tawil syndrome yearly screening with the following should be considered | * But when a patient with positive KCNJ2 mutation and have no symtoms in Andersen-Tawil syndrome yearly screening with the following should be considered: | ||
** A 12-lead ECG | ** A 12-lead ECG<ref name="pmid203014412">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K et al.| title=GeneReviews® | journal= | year= 1993 | volume= | issue= | pages= | pmid=20301441 | doi= | pmc= | url= }}</ref> | ||
** 24-hour Holter monitoring | ** 24-hour Holter monitoring | ||
Revision as of 21:01, 30 January 2020
Xyz Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Andersen-Tawil syndrome screening On the Web |
American Roentgen Ray Society Images of Andersen-Tawil syndrome screening |
Risk calculators and risk factors for Andersen-Tawil syndrome screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There is insufficient evidence to recommend routine screening for Andersen-Tawil syndrome.
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Screening
- There is insufficient evidence to recommend routine screening for Andersen-Tawil syndrome.
- But when a patient with positive KCNJ2 mutation and have no symtoms in Andersen-Tawil syndrome yearly screening with the following should be considered:
- A 12-lead ECG[1]
- 24-hour Holter monitoring
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
- [Condition 1]
- [Condition 2]
- [Condition 3]